Carbidopa
Carbidopa
Definition
A hydrazine derivative of dopa. Carbidopa is a peripheral dopa decarboxylase inhibitor that is used as an adjunct to levodopa administration to prevent peripheral biosynthesis of levodopa to dopamine, thereby reducing peripheral side effects. Carbidopa does not penetrate the blood brain barrier so that levodopa, after it reaches the brain, can be metabolized to dopamine by dopa decarboxylase where it exerts its effect on dopamine receptors.
Also known as (-)-L-alpha-Hydrazino-3,4-dihydroxy-alpha-methylhydrocinnamic Acid, alpha-Methyldopahydrazine, Benzenepropanoic Acid, alpha-hydrazino-3,4-dihydroxy-alpha-methyl-,(S)-, Carbidopa, CARBIDOPA HYDRATE, Lodosyn — per NCIT
Also identified as
- NCIT NCIT:C47431 per NCIT
- SCTID 386107009 per RXNORM
- SCTID 73579000 per RXNORM
- UNII MNX7R8C5VO per RXNORM
Indications
| Disease | Relation | Source |
|---|---|---|
| Parkinson's disease | may treat | MEDRT · Public domain (U.S. Government work) |
Organ Effects
| Organ | Side effect / interaction | Source |
|---|---|---|
| Central nervous system | may treat a disease of this organ | DERIVED · CC BY 4.0 |
| Nervous system | may treat a disease of this organ | DERIVED · CC BY 4.0 |
2 entries above are marked DERIVED: Atlas Médico inferred them by combining two sourced claims, and no source asserts these links directly. Treat them as a navigation aid, not as a clinical statement.